Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
NIZORAL is a topical antifungal shampoo containing ketoconazole, approved in 1990 for the treatment of fungal scalp infections and seborrheic dermatitis. It works by inhibiting fungal cell membrane synthesis, reducing fungal burden on the scalp. This small-molecule topical product represents a mature, well-established dermatology offering.
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive positioning and focus on brand loyalty and formulation differentiation rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NIZORAL offers stability in a mature franchise but limited growth trajectory; career advancement likely depends on operational excellence, defensive strategy execution, and cost optimization rather than innovation or pipeline expansion. This role suits professionals seeking established market experience or interested in dermatology/OTC portfolio management in a defensive posture.
Worked on NIZORAL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.